Use and safety of trastuzumab emtansin in HER2+metastatic breast cancer in a tertiary hospital

被引：0
|
作者：
Chaguaceda Galisteo, C. [1 ]
Manzaneque Gordon, Alba [1 ]
Del Rio Torres, Hector Jose [1 ]
Baro, Natalia Creus [1 ]
机构：
[1] Hosp Clin Barcelona, Pharm, Barcelona, Spain
来源：
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY | 2017年 / 39卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
HP-PC097
引用
收藏
页码：286 / 286
页数：1
相关论文
共 50 条
  • [1] Bevacizumab plus trastuzumab for treatment of HER2+metastatic breast cancer
    De Amuriza Chicharro, N.
    Gastalver Martin, C.
    Goyache Goni, M. P.
    Cortijo Cascajares, S.
    Garcia Munoz, C.
    Ferrari Piquero, J. M.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2013, 35 (05) : 984 - 985
  • [2] The association of centromere amplification and response to trastuzumab in HER2+metastatic breast cancer
    Andrieu, Charlotte
    Al-Sultan, Dalal
    Ivers, Laura
    Pina, Jose Javier Berenguer
    Skrobo, Darko
    Ballot, Josephine
    Eustace, Alex J.
    Gullo, Giuseppe
    Crown, John
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [3] Study of the combination gemcitabine and trastuzumab in the treatment of HER2+metastatic breast cancer
    Menjon-Beltran, S.
    Olivencia-Dueso, R.
    Gonzalez-Jimenez, E.
    Titos, M. J.
    BREAST CANCER RESEARCH, 2007, 9 (01)
  • [4] Survival of patients with HER2+metastatic breast cancer and use of trastuzumab following progression: analysis of RegistHER
    Rugo, H.
    Kaufman, P.
    Tan-Chiu, E.
    Ulcickas, Yood M.
    Paik, S.
    Yardley, D.
    Brufsky, A.
    Mayer, M.
    Birkner, M.
    Wang, L.
    Brammer, M.
    Tripathy, D.
    CANCER RESEARCH, 2009, 69 (02) : 245S - 245S
  • [5] Trastuzumab for HER2+metastatic breast cancer in clinical practice: Cardiotoxicity and overall survival
    Rossi, Marta
    Carioli, Greta
    Bonifazi, Martina
    Zambelli, Alberto
    Franchi, Matteo
    Moja, Lorenzo
    Zambon, Antonella
    Corrao, Giovanni
    La Vecchia, Carlo
    Zocchetti, Carlo
    Negri, Eva
    EUROPEAN JOURNAL OF CANCER, 2016, 52 : 41 - 49
  • [6] Predictors of survival in patients with HER2+metastatic breast cancer (MBC) treated with trastuzumab
    Olson, E. M.
    Najita, J. S.
    Sohl, J.
    Arnaout, A.
    Winer, E. P.
    Lin, N. U.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [7] COST-EFFECTIVENESS ANALYSIS OF TRASTUZUMAB DERUXTECAN FOR PATIENTS WITH HER2+METASTATIC BREAST CANCER
    Mudumba, R.
    Chan, H.
    Cheng, Y. Y.
    Wang, C. C.
    Correia, L.
    Ballreich, J.
    Levy, J.
    VALUE IN HEALTH, 2022, 25 (12) : S95 - S95
  • [8] Trastuzumab emtansine, an antibody-drug conjugate for the treatment of HER2+metastatic breast cancer
    Niculescu-Duvaz, Ion
    CURRENT OPINION IN MOLECULAR THERAPEUTICS, 2010, 12 (03) : 350 - 360
  • [9] Trastuzumab and vinorelbine or taxane chemotherapy for HER2+metastatic breast cancer: The TRAVIOTA study.
    Burstein, H. J.
    Keshaviah, A.
    Baron, A.
    Hart, R.
    Lambert-Falls, R.
    Marcom, P. K.
    Gelman, R.
    Winer, E. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 40S - 40S
  • [10] Evolving HER2+Metastatic Breast Cancer Landscape
    Seidman, Andrew D.
    Bardia, Aditya
    Pegram, Mark
    Rao, Ruta
    ONCOLOGY-NEW YORK, 2021, 35 (12): : 839 - 842
12345